#biomarin
Latest news and interesting information about biomarin.
BioMarin Neutral Rating, $50 Target by HC Wainwright
H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.
BioMarin stock surges on positive hypochondroplasia trial data
BioMarin stock jumped 4.8% after positive Phase 3 trial results for VOXZOGO in hypochondroplasia, showing significant growth improvements.
Biotech at Inflection Point: JPMorgan Covers 14 Firms | Bond.az
JPMorgan covers 14 biotech firms at inflection point, with ratings and price targets. See which companies are poised for growth and the catalysts ahead.
...


